ES8605681A1 - Procedimiento para la obtencion de glicoproteinas antitumo- rales modificadas en sus motivos glucidicos - Google Patents

Procedimiento para la obtencion de glicoproteinas antitumo- rales modificadas en sus motivos glucidicos

Info

Publication number
ES8605681A1
ES8605681A1 ES544337A ES544337A ES8605681A1 ES 8605681 A1 ES8605681 A1 ES 8605681A1 ES 544337 A ES544337 A ES 544337A ES 544337 A ES544337 A ES 544337A ES 8605681 A1 ES8605681 A1 ES 8605681A1
Authority
ES
Spain
Prior art keywords
glycoprotein
antitumour
obtaining
modified
carbohydrate moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES544337A
Other languages
English (en)
Other versions
ES544337A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8409703A external-priority patent/FR2566271B1/fr
Priority claimed from FR8502067A external-priority patent/FR2577137B1/fr
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of ES8605681A1 publication Critical patent/ES8605681A1/es
Publication of ES544337A0 publication Critical patent/ES544337A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE GLICOPROTEINAS ANTITUMORALES, MODIFICADAS EN SUS MOTIVOS GLUCIDICOS. CONSISTE EN TRATAR UNA SOLUCION ACUOSA DE UNA CICLOPROTEINA INACTIVADORA DE LOS RIBOSOMAS, CUYOS GRUPOS TIOLICOS ESTAN EVENTUALMENTE PROTEGIDOS, CON UNA SOLUCION ACUOSA DE UN PERYODATO ALCALINO, DURANTE UN PERIODO DE TIEMPO COMPRENDIDO ENTRE 0,2 Y 24 HORAS, A UNA TEMPERATURA ENTRE 0 Y 15 GRADOS Y AL RESGUARDO DE LA LUZ, A CONTINUACION SE DESBLOQUEA EVENTUALMENTE EL GRUPO TIOLICO Y SE AISLA EL PRODUCTO FINAL. EN CALIDAD DE GLICOPROTEINA DE PARTIDA SE UTILIZA LA CADENA A DE LA RICINA, LA GELONINA, LA GPIR MOM O LA GPIR DIANTINA 30. DE APLICACION EN MEDICINA Y FARMACIA POR SUS PROPIEDADES FARMACOCINETICAS.
ES544337A 1984-06-20 1985-06-19 Procedimiento para la obtencion de glicoproteinas antitumo- rales modificadas en sus motivos glucidicos Expired ES8605681A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8409703A FR2566271B1 (fr) 1984-06-20 1984-06-20 Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
FR8502067A FR2577137B1 (fr) 1985-02-13 1985-02-13 Glycoproteines antitumorales, modifiees sur leurs motifs glucidiques

Publications (2)

Publication Number Publication Date
ES8605681A1 true ES8605681A1 (es) 1986-04-01
ES544337A0 ES544337A0 (es) 1986-04-01

Family

ID=26224020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES544337A Expired ES8605681A1 (es) 1984-06-20 1985-06-19 Procedimiento para la obtencion de glicoproteinas antitumo- rales modificadas en sus motivos glucidicos

Country Status (14)

Country Link
EP (1) EP0172045B1 (es)
JP (1) JPS6112628A (es)
KR (1) KR930000058B1 (es)
AT (1) ATE40700T1 (es)
AU (1) AU593211B2 (es)
CA (1) CA1248874A (es)
DE (1) DE3568167D1 (es)
DK (1) DK166626B1 (es)
ES (1) ES8605681A1 (es)
GR (1) GR851497B (es)
IE (1) IE58514B1 (es)
IL (1) IL75484A0 (es)
NZ (1) NZ212439A (es)
PT (1) PT80662B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
FR2602682B1 (fr) * 1986-08-12 1988-12-02 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5250532A (en) * 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
GB9808485D0 (en) * 1998-04-21 1998-06-17 Univ Cambridge Tech Improvements relating to immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤

Also Published As

Publication number Publication date
DK166626B1 (da) 1993-06-21
KR930000058B1 (ko) 1993-01-06
KR860000315A (ko) 1986-01-28
DE3568167D1 (en) 1989-03-16
JPH0582400B2 (es) 1993-11-18
ES544337A0 (es) 1986-04-01
DK277985A (da) 1985-12-21
IL75484A0 (en) 1985-10-31
PT80662A (en) 1985-07-01
GR851497B (es) 1985-11-25
IE58514B1 (en) 1993-10-06
DK277985D0 (da) 1985-06-19
PT80662B (en) 1986-12-09
ATE40700T1 (de) 1989-02-15
EP0172045B1 (fr) 1989-02-08
AU593211B2 (en) 1990-02-08
IE851511L (en) 1985-12-20
EP0172045A1 (fr) 1986-02-19
JPS6112628A (ja) 1986-01-21
CA1248874A (en) 1989-01-17
NZ212439A (en) 1989-01-27
AU4364685A (en) 1986-01-02

Similar Documents

Publication Publication Date Title
AU585131B2 (en) New aryl-substituted (N-piperidinyl)methyl- and (N-piperazinyl)methylazoles having antipsychotic properties
ES8605681A1 (es) Procedimiento para la obtencion de glicoproteinas antitumo- rales modificadas en sus motivos glucidicos
AU573531B2 (en) Human lymphotoxin
JPS57134465A (en) Manufacture of 1,5-didesoxy-1,5-imino-d- glucitol or n-derivative thereof
ES8107253A1 (es) Procedimiento para la fabricacion de derivados de la quitina
ES8608932A1 (es) Procedimiento e instalacion para la separacion de partes me-talicas de partes no metalicas
EP0100521A3 (en) Process for the production of a herpes antigen, appropriate means therefor and a process for its production, and the use of this antigen
IE890607L (en) Antihypertensive hyperimmune milk, production, composition, and use
EP0466995A3 (en) Sucrose phosphate synthase (sps), its process for preparation, its cdna, and utilization of cdna to modify the expression of sps in the plant cells
AU538381B2 (en) Process of treating dust containing zinc + lead
DE2861983D1 (en) Rubber-modified terpolymer and process for its production
GB2118796B (en) Improvements in or relating to amplifier circuits for high impedance signals sources
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
GR852050B (es)
ES8705496A1 (es) Procedimiento para aislar poliarilensulfuros
JPS51144328A (en) Process for producing high tensile strength bolts with high yield rati o
IL62936A (en) Process for the beneficiation of phosphate ore
MY105082A (en) Separation process
CA1029198A (en) Pollution-free process for treating copper sulfide flotation concentrates and recovering copper
JPS5541013A (en) Gain control circuit
JPS5214518A (en) Process for manufacturing a rotatable drum for the centrifugal separat or for concentrating uranium
Tikhonov et al. Optimization of the Flotation Process at the Pechenganickel Smelter
DE3270177D1 (en) Process for purifying elastase
GB1071127A (en) Deoxidation of copper and its alloys
Sun et al. New Techniques for Less Collector and Collector-Free Flotation of Copper Sulphide Minerals--a Study

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970612